Variability of CSF alzheimer's disease biomarkers: Implications for clinical practice

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Vos, Stephanie J B ^a   Visser, Pieter Jelle ^a,b   Verhey, Frans ^a   Aalten, Pauline ^a   Knol, Dirk ^b   Ramakers, Inez ^a   Scheltens, Philip ^b   Olde Rikkert, Marcel G M ^c,d   Verbeek, Marcel M ^c,d   Teunissen, Charlotte E ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN; AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTERLABORATORY VARIABILITY; INTRALABORATORY VARIABILITY; PROTEIN CEREBROSPINAL FLUID LEVEL; STATISTICAL CONCEPTS; CLINICAL TRIAL; MULTICENTER STUDY; REPRODUCIBILITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; HUMANS; REPRODUCIBILITY OF RESULTS; TAU PROTEINS;

EID: 84903530894     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100784     Document Type: Article

References (20)

1. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer's disease. Lancet Neurol 2: 605-613. (Pubitemid 37162569)
2. Fagan AM, Holtzman DM (2010) Cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 4: 51-63.
3. Vos SJB, van Rossum IA, Verhey F, Knol DL, Soininen H, et al. (2013) Prediction of Alzheimer's disease in subjects with amnestic and non-amnestic MCI. Neurology 80: 1124-1132.
4. Dumurgier J, Vercruysse O, Paquet C, Bombois S, Chaulet C, et al. (2012) Intersite variability of CSF Alzheimer's disease biomarkers in clinical setting. Alzheimers Dement. DOI:10.1016/j.jalz.2012.06.006
5. Lewczuk P, Beck G, Ganslandt O, Esselmann H, Deisenhammer F, et al. (2006) International quality control survey of neurochemical dementia diagnostics. Neurosci Lett 409: 1-4. (Pubitemid 44740057)
6. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, et al. (2011) The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7: 386-395.
7. Verwey NA, van der Flier WM, Blennow K, Clark C, Sokolow S, et al. (2009) A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem 46: 235-240.
8. Handels RL, Aalten P, Wolfs CA, Olde Rikkert M, Scheltens P, et al. (2012) Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study. BMC Neurol 12: 72.
9. Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA (2010) Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid beta(1-42), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. Int J Alzheimers Dis. doi:10.4061/2010/635053.
10. Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, et al. (2010) Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 56: 248-253.
11. de Jong D, Kremer BP, Olde Rikkert MG, Verbeek MM (2007) Current state and future directions of neurochemical biomarkers for Alzheimer's disease. Clin Chem Lab Med 45: 1421-1434. (Pubitemid 350036575)
12. Shrout PE (1998) Measurement reliability and agreement in psychiatry. In Stat Methods Med Res, 7: 301-317.
13. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1: 307-310. (Pubitemid 16134762)
14. Dunn G (2007) Regression models for method comparison data. Journal of Biopharmaceutical Statistics 17: 739-756.
15. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, et al. (2012) Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 6: 419-430.
16. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, et al. (2005) Effects of processing and storage conditions on amyloid beta(1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 51: 189-195. (Pubitemid 40024030)
17. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, et al. (2012) Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement 8: 65-73.
18. Spies PE, Claassen JA, Peer PG, Blankenstein MA, Teunissen CE, et al. (2012) A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Alzheimers Dement; doi:10.1016/j.jalz.2012.01. 010.
19. Hort J, O'Brien JT, Gainotti G, Pirttila T, Popescu BO, et al. (2010). EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol 17: 1236-1248.
20. Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, et al. (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 257-262.